image: Researchers identified a single-domain antibody (VHH6) that preferentially recognizes an oxytetracycline-bound DNA aptamer. Using cDNA display technology, researchers identified a promising antibody, VHH6, whose binding affinity for the DNA aptamer increased in the presence of OTC. Surface plasmon resonance (SPR) analysis confirmed the binding behavior, while AlphaFold3 provided a predicted model of the antibody–DNA interaction. The findings suggest that the three-dimensional structure of DNA plays an important role in antibody recognition.
Credit: Nayab Khaliq et al., Saitama University, Antibodies (2026), 15, 107. Licensed under CC BY 4.0. https://doi.org/10.3390/antib15060107
DNA aptamers are attracting attention as alternatives to antibodies in biosensing and diagnostics. Yet little is known about whether antibodies themselves can recognize the folded structures of DNA aptamers. Researchers at Saitama University have now identified a VHH antibody that preferentially binds an oxytetracycline-associated DNA aptamer. One example is a DNA aptamer, a short, single-stranded DNA molecule that folds into a specific shape and selectively binds to a target, such as a protein or small chemical compound. Because of their molecular recognition capabilities, DNA aptamers are attracting growing interest as alternatives to conventional antibodies in biosensors, diagnostics, and other biotechnology applications.
Most research on DNA aptamers has focused on identifying DNA molecules that recognize specific targets. However, the reverse approach—developing proteins or antibodies that recognize the three-dimensional structures of DNA aptamers—remains relatively unexplored. Although antibodies capable of recognizing certain specialized DNA structures have been reported, identifying antibodies that recognize the diverse folded structures of single-stranded DNA aptamers presents a new challenge. Such antibodies could provide new ways to detect changes in DNA structure and potentially expand the possibilities for molecular sensing.
A research team led by Specially Appointed Professor Naoto Nemoto and Professor Koji Matsuoka of the Graduate School of Science and Engineering at Saitama University aimed to determine whether small, single-domain antibodies known as VHH antibodies could recognize the three-dimensional structural characteristics of DNA aptamers. The researchers focused on a DNA aptamer that binds to oxytetracycline (OTC), an antibiotic used in veterinary medicine, and investigated how its interaction with VHH antibodies changes depending on the presence or absence of OTC. Using cDNA display technology to screen antibody candidates, surface plasmon resonance to measure their binding properties, and AlphaFold3 to predict molecular interactions, the team successfully identified a promising VHH antibody, designated VHH6, whose binding behavior is influenced by the structural characteristics of the DNA aptamer. This study expands the scope of antibody recognition beyond proteins to folded nucleic-acid structures. The study was published online on 11 November 2026 in the journal Antibodies.
Key findings of the study include:
- Identification of a DNA aptamer-binding antibody: Using four rounds of in vitro selection with cDNA display technology, the researchers obtained VHH antibody candidates and identified VHH6 as a promising antibody that recognizes structural features of a DNA aptamer.
- Stronger binding in the presence of an antibiotic: VHH6 exhibited approximately 4.2-fold higher binding affinity for the DNA aptamer in the presence of OTC than in its absence, indicating that OTC influences the stability of the antibody–aptamer interaction.
- Evidence of sequence-dependent molecular recognition: When the DNA sequence was rearranged while maintaining the same overall base composition, VHH6 showed weaker binding, suggesting that the DNA aptamer's sequence-dependent three-dimensional structure contributes to recognition.
- Insights into the molecular recognition mechanism: AlphaFold3 structural predictions suggested that aromatic and positively charged amino acid residues in the antibody's CDR3 region may contribute to interactions with DNA bases and the phosphate backbone.
- A potential foundation for new molecular sensing technologies: The findings suggest that combining DNA aptamers with structure-sensitive VHH antibodies could provide a new approach to developing biosensors for small molecules.
“This study is interesting because it explores molecular recognition from the opposite direction to conventional DNA aptamer research,” says Nayab Khaliq, a doctoral candidate and first author of the study. “Rather than using DNA to recognize a target molecule, we investigated whether an antibody could recognize the three-dimensional features of DNA itself. Our results suggest that the folded structure of a DNA aptamer, as well as the presence of a molecule bound to it, can influence its interaction with an antibody. This opens up new possibilities for understanding and engineering protein–nucleic acid interactions.”
The findings also provide a starting point for developing molecular detection systems that combine the target-binding ability of DNA aptamers with the recognition capabilities of VHH antibodies. For example, a DNA aptamer could first capture a small chemical compound, while an antibody could then recognize structural features associated with the resulting aptamer–target complex. Such an approach might eventually enable the development of a sandwich-like detection system for small molecules that are difficult to measure using conventional antibody-based assays.
Looking five to ten years ahead, further improvements in aptamer design, antibody specificity, and detection sensitivity could help translate this concept into practical biosensors for food safety, environmental monitoring, and biotechnology. In particular, detecting antibiotic residues in animal-derived food products represents a potential application. However, additional research will be necessary to develop aptamers with more pronounced target-dependent structural changes and to establish reliable analytical performance.
“Our long-term goal is to create new molecular recognition technologies by combining the strengths of DNA aptamers and antibodies,” says Specially Appointed Professor Nemoto. “If we can design aptamers that change their structures more distinctly when capturing small molecules, and antibodies that recognize those changes with high specificity, we may be able to create new detection tools for substances that are difficult to measure using existing methods. We hope this research will eventually contribute to safer food supplies, improved environmental monitoring, and broader applications in molecular diagnostics.”
Journal
Antibodies
Article Title
In Vitro Selection of VHH Antibodies That Recognize the Tertiary Structure of Single-Stranded DNA Aptamers
Article Publication Date
11-Nov-2026